8-K
filed June 2, 2026, 5:20 PM ET
CIK 0001845459
debt
confidence high
sentiment neutral
materiality 0.65
NKGen Biotech secures $2.42M additional loan from AlpineBrook; conversion price $0.08
NKGen Biotech, Inc.
- Additional loan of $2.42M (net $2.2M after $220k fee) issued as convertible note with $0.08/sh conversion price.
- New warrant issued for shares at $0.08/exercise price, 10-year term, cashless exercise permitted.
- Consideration shares increased to 12,953,947, payable in 6 installments over 30 months from closing.
- Voting agreement with major stockholders to approve share increase within 2 months or before next financing.
- Third amendment to existing secured convertible loan; total debt now includes multiple notes and warrants.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued convertible note to Lender.
- Security
- convertible note
- Purchaser
- Lender
Exact text from the filing
(b) the Additional Note #3, which is convertible into shares of Common Stock at a conversion price of $0.08 per share, subject to adjustment
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.7
NKGen Biotech, Inc. issued common stock to Lender.
- Security
- common stock
- Purchaser
- Lender
Exact text from the filing
(a) The Consideration Shares to be issued in six installments commencing on the five-month anniversary of the closing date of the Loan Agreement
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued warrant to Lender.
- Security
- warrant
- Purchaser
- Lender
Exact text from the filing
(c) the Additional Warrant #3, which is exercisable for shares of Common Stock at an exercise price of $0.08 per share, subject to adjustment
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NKGen Biotech, Inc. amended Third Omnibus Amendment to Secured Convertible Loan Agreement and Warrants with AlpineBrook Capital GP I Limited valued at $2,420,000 (effective 2026-05-27).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- AlpineBrook Capital GP I Limited
- Value
- $2,420,000
- Effective
- 2026-05-27
Exact text from the filing
On May 27, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ NKGen OpCo ,” and together with the Company, the “ Borrowers ”), entered into a Third Omnibus Amendment to Secured Convertible Loan Agreement and Warrants (the “ Third Amendment ”) with AlpineBrook Capital GP I Limited (the “ Lender ”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.